BridgeBio Pharma (BBIO) Non-cash Items (2018 - 2025)

BridgeBio Pharma has disclosed Non-cash Items across 8 years of filings, most recently posting $12.6 million for Q2 2025.

• Non-cash Items for Q2 2025 came in at $12.6 million, down 80.92% year-over-year; the trailing twelve-month figure through Jun 2025 was $12.6 million (down 80.92% YoY), and the FY2024 annual result was $78.8 million, up 149.41% from the prior year.
• Non-cash Items came in at $12.6 million for Q2 2025 at BridgeBio Pharma, up from $9.0 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $105.6 million in Q2 2021 to a low of $323304.0 in Q3 2023.
• The 5-year median for Non-cash Items is $8.9 million (2024), against an average of $22.9 million.
• Across the five-year window, Non-cash Items sank 99.6% in 2022 and soared 19661.94% in 2024, its largest moves.
• BridgeBio Pharma's Non-cash Items stood at $10.1 million in 2021, then tumbled by 77.87% to $2.2 million in 2022, then soared by 1306.06% to $31.6 million in 2023, then jumped by 149.41% to $78.8 million in 2024, then sank by 83.98% to $12.6 million in 2025.
• The last three Non-cash Items figures came in at $12.6 million (Q2 2025), $9.0 million (Q1 2025), and $78.8 million (Q4 2024), per Business Quant data.